Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121692) titled 'A clinical study of retlirafusp alfa combined with platinum-based chemotherapy and apatinib as first-line treatment for advanced NSCLC' on April 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The first affiliated hospital of anhui medical university
Condition:
non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-04-01
Target Sample Size: Experimental group:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=316757
Published by HT Digital Content Services with permission...